In addition, the clinical and genetic characteristics of different phenotypes of acromelic dysplasia due to identical FBN1 gene mutations and the efficacy of recombinant human growth hormone (rhGH) therapy in acromelic dysplasia are summarized. This evidence concerns the gene GH1 and acromelic dysplasia.